Aethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a note issued to investors on Thursday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright dropped their price objective on Aethlon Medical from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, June 24th.

Aethlon Medical Stock Down 8.5 %

Shares of AEMD stock opened at $0.35 on Thursday. Aethlon Medical has a 12 month low of $0.24 and a 12 month high of $2.93. The company has a market cap of $4.83 million, a PE ratio of -0.07 and a beta of 1.65. The business’s 50 day moving average is $0.40 and its two-hundred day moving average is $0.92.

Aethlon Medical (NASDAQ:AEMD) last posted its earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.10. During the same quarter last year, the business earned ($1.30) earnings per share. As a group, equities analysts expect that Aethlon Medical will post -1.1 EPS for the current fiscal year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.